FLT3 inhibition in acute myeloid leukaemia

被引:10
作者
Daver, Naval [1 ]
Kantarjian, Hagop [1 ]
机构
[1] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
关键词
MUTATIONS; THERAPY;
D O I
10.1016/S1470-2045(17)30509-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:988 / 989
页数:2
相关论文
共 10 条
[1]  
[Anonymous], 2014, BLOOD, DOI DOI 10.1182/BLOOD.V124.21.389.389
[2]   Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML) [J].
Cortes, Jorge E. ;
Tallman, Martin S. ;
Schiller, Gary ;
Trone, Denise ;
Gammon, Guy ;
Goldberg, Stuart ;
Perl, Alexander E. ;
Marie, Jean Pierre ;
Martinelli, Giovanni ;
Levis, Mark .
BLOOD, 2013, 122 (21)
[3]   Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status [J].
Cortes, Jorge E. ;
Kantarjian, Hagop ;
Foran, James M. ;
Ghirdaladze, Darejan ;
Zodelava, Mamia ;
Borthakur, Gautam ;
Gammon, Guy ;
Trone, Denise ;
Armstrong, Robert C. ;
James, Joyce ;
Levis, Mark .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) :3681-+
[4]   Secondary mutations as mediators of resistance to targeted therapy in leukemia [J].
Daver, Naval ;
Cortes, Jorge ;
Ravandi, Farhad ;
Patel, Keyur P. ;
Burger, Jan A. ;
Konopleva, Marina ;
Kantarjian, Hagop .
BLOOD, 2015, 125 (21) :3236-3245
[5]   Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study [J].
Deininger, Michael W. ;
Cortes, Jorge E. ;
Kantarjian, Hagop M. ;
Shah, Neil ;
Bixby, Dale ;
Mauro, Michael J. ;
Flinn, Ian W. ;
O'Hare, Thomas ;
Hu, Simin ;
Dorer, David J. ;
Rivera, Victor M. ;
Clackson, Tim ;
Turner, Christopher D. ;
Haluska, Frank G. ;
Druker, Brian J. ;
Talpaz, Moshe .
BLOOD, 2012, 120 (21)
[6]   Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study [J].
Perl, Alexander E. ;
Altman, Jessica K. ;
Cortes, Jorge ;
Smith, Catherine ;
Litzow, Mark ;
Baer, Maria R. ;
Claxton, David ;
Erba, Harry P. ;
Gill, Stan ;
Goldberg, Stuart ;
Jurcic, Joseph G. ;
Larson, Richard A. ;
Liu, Chaofeng ;
Ritchie, Ellen ;
Schiller, Gary ;
Spira, Alexander I. ;
Strickland, Stephen A. ;
Tibes, Raoul ;
Ustun, Celalettin ;
Wang, Eunice S. ;
Stuart, Robert ;
Roellig, Christoph ;
Neubauer, Andreas ;
Martinelli, Giovanni ;
Bahceci, Erkut ;
Levis, Mark .
LANCET ONCOLOGY, 2017, 18 (08) :1061-1075
[7]   Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation [J].
Ravandi, Farhad ;
Alattar, Mona Lisa ;
Grunwald, Michael R. ;
Rudek, Michelle A. ;
Rajkhowa, Trivikram ;
Richie, Mary Ann ;
Pierce, Sherry ;
Daver, Naval ;
Garcia-Manero, Guillermo ;
Faderl, Stefan ;
Nazha, Aziz ;
Konopleva, Marina ;
Borthakur, Gautam ;
Burger, Jan ;
Kadia, Tapan ;
Dellasala, Sara ;
Andreeff, Michael ;
Cortes, Jorge ;
Kantarjian, Hagop ;
Levis, Mark .
BLOOD, 2013, 121 (23) :4655-4662
[8]  
Stone RM., 2015, Blood, V126, P6, DOI DOI 10.1182/blood.V126.23.6.6
[9]   Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD [J].
Takahashi, Koichi ;
Kantarjian, Hagop ;
Pemmaraju, Naveen ;
Andreeff, Michael ;
Borthakur, Gautam ;
Faderl, Stefan ;
Garcia-Manero, Guillermo ;
Pierce, Sherry ;
Luthra, Rajyalakshmi ;
Cardenas-Turanzas, Marylou ;
Estrov, Zeev ;
Ravandi, Farhad ;
Cortes, Jorge .
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (05) :659-666
[10]   Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis [J].
Thiede, C ;
Steudel, C ;
Mohr, B ;
Schaich, M ;
Schäkel, U ;
Platzbecker, U ;
Wermke, M ;
Bornhäuser, M ;
Ritter, M ;
Neubauer, A ;
Ehninger, G ;
Illmer, T .
BLOOD, 2002, 99 (12) :4326-4335